scholarly journals Congenital mesoblastic nephroma. Own experience of the Research Institute of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

2020 ◽  
Vol 6 (4) ◽  
pp. 25-32
Author(s):  
G. B. Sagoyan ◽  
M. V. Rubanskaya ◽  
D. V. Shevtsov ◽  
M. A. Rubanskiy ◽  
P. A. Kerimov ◽  
...  
Keyword(s):  
Medical Research ◽  
Pediatric Oncology ◽  
Research Centre ◽  
Mesoblastic Nephroma ◽  
Ministry Of Health ◽  
National Medical ◽  
Congenital Mesoblastic Nephroma ◽  
Research Institute

scholarly journals The experience of managing children and adolescents with Ewing’s sarcoma in the Pediatric Oncology Department of the Federal State Budgetary Institution “National Medical Research Center of Oncology”, Ministry of Health of Russia

2021 ◽  
Vol 8 (2) ◽  
pp. 26-34
Author(s):  
D. Yu. Yurchenko ◽  
S. A. Kuznetsov ◽  
Yu. Yu. Kozel ◽  
E. M. Frantsiyants ◽  
G. A. Mkrtchyan ◽  
...  
Keyword(s):  
Medical Research ◽  
Children And Adolescents ◽  
Pediatric Oncology ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Research Center ◽  
Ministry Of Health ◽  
General Group ◽  
National Medical ◽  
Adolescent Patients

Relevance. One of the leading positions among malignant tumors of the musculoskeletal system in children and adolescents has recently begun to be occupied by Ewing’s sarcoma (ES). The prognosis of patients suffering from this onconosology remains extremely unfavorable even in the absence of distant metastases and timely initiation of antitumor treatment. The authors present 10 years of experience in the management of pediatric and adolescent patients with ES in the pediatric oncology department of the National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included pediatric and adolescent patients diagnosed with ES of I—IV stages of various localizations, who were treated in the Pediatric Oncology Department of the National Medical Research Center of Oncology, Ministry of Health of Russia in the period from 2009 to 2019. We analyzed 2- and 5-year overall (OS) and event-free (EFS) survival in patients who received combined and complex antitumor treatment for various forms of tumor dissemination according to the EURO-EWING 2008protocol, which included neo-and adjuvant polychemotherapy, including high-dose, radical surgical treatment, and also radiation therapy.Results. The median 5-year OS and EFS in the general group of the studied formulations was 60 and 17 months, respectively. The indicators of 2- and 5-year OS and EFS in patients of the general group were 80.6 % and 56.7 %, 38.6 % and 10.6 %, respectively. The volume of the performed antitumor treatment, as well as the form of the advanced tumor process, did not have a significant effect on OS and EFS indicators (p > 0.05). At the same time, the chances of developing ES in boys were statistically significantly higher by 2.2 times in comparison with girls (95 % confidence interval 1.1—4.3).Conclusion. The obtained OS and EFS indices indicate unsatisfactory results of anticancer therapy and extremely high aggressiveness of the biological behavior of the tumor, regardless of the form of spread of the tumor process.

scholarly journals Novalis Tx radiosurgical platform experience in National Medical Research Centre for Oncology of the Ministry of Health of Russian

2020 ◽  
Vol 1 (4) ◽  
pp. 32-37
Author(s):  
O. I. Kit ◽  
V. I. Voshedskii ◽  
P. G. Sakun ◽  
M. A. Gusareva ◽  
S. G. Vlasov ◽  
...  
Keyword(s):  
Medical Research ◽  
Research Centre ◽  
Ministry Of Health ◽  
National Medical

scholarly journals Infectious safety during primary specialized accreditation in the COVID-19 pandemic

2021 ◽  
pp. 14-20
Author(s):  
Evgeny Germanovich Ripp ◽  
A. R. Fattakhov ◽  
T. M. Ripp ◽  
R. A. Postanogov ◽  
N. M. Iminov ◽  
...  
Keyword(s):  
Medical Education ◽  
Medical Research ◽  
Research Centre ◽  
Face To Face ◽  
Technological Processes ◽  
Specialized Accreditation ◽  
National Medical ◽  
Technical Personnel ◽  
The Face ◽  
Simulation Center

This article is devoted to the organization of the work of the Accreditation and Simulation Center of the Institute of Medical Education of the Almazov National Medical Research Centre during the primary specialized accreditation in the COVID-19 pandemic. Organizational solutions, technological processes and routing of accredited (308 people), support and technical personnel (98 people) and employees of the Accreditation and Simulation Center (14 people) and members of accreditation commissions (67 people) are presented to ensure infectious safety and the effectiveness of the face-to-face practice-oriented stage of accreditation.

scholarly journals Twenty-year experience of examining biopsies of signal lymph nodes in breast cancer

2020 ◽  
Vol 16 (1) ◽  
pp. 12-20 ◽  
Author(s):  
V. F. Semiglazov ◽  
P. V. Krivorotko ◽  
E. K. Zhiltsova ◽  
S. V. Kanaev ◽  
E. S. Trufanova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Diagnostic Accuracy ◽  
Medical Research ◽  
Systemic Therapy ◽  
False Positive ◽  
Ministry Of Health ◽  
National Medical ◽  
Neoadjuvant Systemic Therapy ◽  
Oncology Center

Biopsy of signal (sentinel) lymph nodes (LN) has been performed at the N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia, for almost 20 years. In the first few years, contrast-visual method (1 % blue isosulfan and triphenyl methane control) was used in 640 patients with early (T1–2N0M0) breast cancer. In 150 patients from this cohort, standard axillary dissection was performed irrespectively of the results of signal (sentinel) biopsy. The rate of false positive responses varied between 4.6 and 6.6 %. Since 2012, radioisotope method of visualization of signal LN with intratumor administration of 99mТс-technephyte colloid particles has been used (in 708 patients with T1–3N0M0 breast cancer). This type of signal LN biopsy had the following diagnostic characteristics: sensitivity was 58.9 %, specificity was 96.2 %, diagnostic accuracy was 87.1 %.In parallel with this study, in 2016 a study of diagnostic accuracy and safety of biopsy of axillary LN after neoadjuvant systemic therapy was started. The study included 263 patients with T1N1–3M0, T2–3N0–3M0, T4N0–1M0 breast cancer. To evaluate clinical status of axillary LN, ultrasound, single-photon emission computed tomography, mammography at baseline and after completion of neoadjuvant chemotherapy ± targeted therapy (trastuzumab) were performed. In some patients, in the recent years a double method of signal LN labeling (radioisotope and fluorescent methods) was used.In patients with baseline cN+-status, the rate of false positive signal LN biopsy conclusions was 13.6 %, in patients with baseline cN0-status it was 7.7 %.The study of double contrast of axillary LN and targeted label of metastatic LN prior to neoadjuvant systemic therapy continues. In total, various modifications of biopsy of signal LN were performed in 2,000 patients with breast cancer.The study protocol was approved by the biomedical ethics committee of N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia.All patients gave written informed consent to participate in the study.

scholarly journals A new indolocarbazole derivative in melanoma and carcinoma lung in vivo treatment

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Anna Lantsova ◽  
Irina Golubeva ◽  
Larisa Borisova ◽  
Lyudmila Nikolaeva ◽  
Lydia Ektova ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Medical Research ◽  
Russian Federation ◽  
Research Center ◽  
Maximum Effect ◽  
Drug Form ◽  
Ministry Of Health ◽  
F1 Hybrid ◽  
National Medical ◽  
Experimental Drug

Abstract Objective The current scientific research direction is development of drugs with a targeted effect on malignant tumors. One of the promising groups is indolocarbazoles and their derivatives, which can initiate various tumor cell death pathways. Russian scientists from N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russian Federation has developed a new experimental drug form of the original compound LCS 1269 with cytotoxic and antiangiogenic properties, blocking vasculogenic mimicry in tumor. The study aim is the experimental drug form LCS 1269 antitumor activity on models of transplantable mouse tumors B-16 melanoma and Lewis epidermoid lung carcinoma (LLC) with different routes and modes of administration. Material and methods Female F1 hybrid mice (C57Bl/6 x DBA/2) and male and female linear mice C57BL/6 were used for management of tumor strains. Mice were obtained from N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russian Federation vivarium. The antitumor effect was assessed by tumor growth inhibition (TGI) and increase of treated animal’s life span (ILS) compared to the control. Results The experimental drug form showed high antitumor activity when administered intravenously once at doses of 100 and 120 mg/kg (TGI = 98–82% and TGI = 95–77%, respectively, ILS = 24%, p < 0.05) on melanoma B-16 mice. On LLC mice, the experimental drug form showed that the intravenous administration route was effective in the range of doses from 60 to 80 mg/kg with a 5 day administration regimen with an interval of 24 h. A dose of 70 mg/kg had maximum effect at the level of TGI = 96–77% (p < 0.05) with its retention for 20 days after the end of treatment. Conclusion The studies have shown that the new compound LCS 1269 in the original drug form, has a pronounced antitumor activity and significantly reduces the volume of tumor mass both on melanoma B-16 and on LLC. It allows us to recommend continue the search for sensitivity of animal transplantable tumors to LCS 1269.

scholarly journals Optimization of the Research and Advisory Department of the Oncological Center

2019 ◽  
pp. 35-39
Author(s):  
Igor Anatolevich Doroshev ◽  
Ivan Sokratovich Stilidi ◽  
Zhanna Aleksandrovna Zavolskaia ◽  
Denis Anatolevich Riabchikov ◽  
Vadim Maratovich Kulushev ◽  
...  
Keyword(s):  
Medical Research ◽  
Medical Care ◽  
Health Facilities ◽  
Research Center ◽  
Medical Institution ◽  
Ministry Of Health ◽  
National Medical ◽  
Quality Of Medical Care ◽  
Oncological Center

The article provides an example of a successful optimization of the work in a research and advisory department of N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russia. All stages of this process are described in detail – from creating a project office and identifying problems to implementing methods for solving them and evaluating results. This work resulted in improving of the quality of medical care provided to the population, which is the most important task of any medical institution. In addition, this optimization experience may be useful for the implementation of similar activities in other health facilities in Russia.

Sign in / Sign up

Export Citation Format

Share Document